Breaking News, Collaborations & Alliances

Avillion, Pearl Therapeutics Sign Clinical Agreement

To advance PT027 through a global clinical development program for the treatment of asthma

Avillion has signed a clinical co-development agreement with Pearl Therapeutics Inc., a wholly owned subsidiary of AstraZeneca, to advance PT027 through a global clinical development program for the treatment of asthma.   PT027 is an investigational fixed dose combination of budesonide (an inhaled corticosteroid) and albuterol (a short-acting beta-2 agonist). Avillion will be responsible for developing PT027 through an extensive clinical development programme and will finance the program...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters